JP2004168768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004168768A5 JP2004168768A5 JP2003369875A JP2003369875A JP2004168768A5 JP 2004168768 A5 JP2004168768 A5 JP 2004168768A5 JP 2003369875 A JP2003369875 A JP 2003369875A JP 2003369875 A JP2003369875 A JP 2003369875A JP 2004168768 A5 JP2004168768 A5 JP 2004168768A5
- Authority
- JP
- Japan
- Prior art keywords
- enoyl
- pyrazol
- fluorophenyl
- prop
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NSVIDGDZEVEYKX-XNTDXEJSSA-N (e)-n-[4-(diethoxyphosphorylmethyl)phenyl]-3-[5-(4-fluorophenyl)-1-methylpyrazol-4-yl]prop-2-enamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)\C=C\C1=C(C=2C=CC(F)=CC=2)N(C)N=C1 NSVIDGDZEVEYKX-XNTDXEJSSA-N 0.000 claims 1
- IIRVGTWONXBBAW-UHFFFAOYSA-M disodium;dioxido(oxo)phosphanium Chemical compound [Na+].[Na+].[O-][P+]([O-])=O IIRVGTWONXBBAW-UHFFFAOYSA-M 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003369875A JP4145230B2 (ja) | 2002-11-01 | 2003-10-30 | 神経障害の予防・治療剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002320153 | 2002-11-01 | ||
| JP2003369875A JP4145230B2 (ja) | 2002-11-01 | 2003-10-30 | 神経障害の予防・治療剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008128851A Division JP2008231115A (ja) | 2002-11-01 | 2008-05-15 | 神経障害の予防・治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004168768A JP2004168768A (ja) | 2004-06-17 |
| JP2004168768A5 true JP2004168768A5 (enExample) | 2008-07-03 |
| JP4145230B2 JP4145230B2 (ja) | 2008-09-03 |
Family
ID=32715932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003369875A Expired - Fee Related JP4145230B2 (ja) | 2002-11-01 | 2003-10-30 | 神経障害の予防・治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4145230B2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0508180A (pt) * | 2004-04-01 | 2007-08-07 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste |
| RU2375358C2 (ru) * | 2004-04-01 | 2009-12-10 | Авентис Фармасьютикалз, Инк. | 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта и их применение |
| WO2006012135A1 (en) * | 2004-06-24 | 2006-02-02 | Janssen Pharmaceutica, N. V. | Quaternary salt ccr2 antagonists |
| JPWO2008010511A1 (ja) * | 2006-07-19 | 2009-12-17 | 武田薬品工業株式会社 | スクリーニング方法 |
| EP1939180A1 (en) * | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| EP4234545A3 (en) | 2011-07-29 | 2023-09-06 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
| JP6006794B2 (ja) * | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| WO2013170068A2 (en) | 2012-05-09 | 2013-11-14 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| EP2968278B8 (en) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| ME03421B (me) | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| EP3397634A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| GB201901559D0 (en) * | 2019-02-05 | 2019-03-27 | Syngenta Crop Protection Ag | Herbicidal compositions |
-
2003
- 2003-10-30 JP JP2003369875A patent/JP4145230B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004168768A5 (enExample) | ||
| JP2008506632A5 (enExample) | ||
| NO20050542L (no) | Fremgangsmate for fremstilling av kalsiumsaltet fra rosuvastatin | |
| JP2005518413A5 (enExample) | ||
| JP2004538039A5 (enExample) | ||
| JP2010507641A5 (enExample) | ||
| AU2003248259A1 (en) | Novel azetidine derivative or salt thereof | |
| JP2003335776A5 (enExample) | ||
| DK1663989T3 (da) | Krystallisk form af bis(E)-7-[4(4-fluorphenyl)-6-isopropyl-2-methyl(methylsulfonyl)aminopyrimidin-5-yl(3R,5S))-3-5-dihydroxyhept-6-ensyrecalciumsalt | |
| HRP20090229T1 (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate | |
| JP2006512924A5 (enExample) | ||
| JP2002053555A5 (enExample) | ||
| JP2006526031A5 (enExample) | ||
| EP1937592A4 (en) | METHOD FOR PRODUCING MICROPOROUS CRYSTALLINE MOLECULAR SIEBS WITH MESOPOROUS FRAME | |
| JP2007508034A5 (enExample) | ||
| CY1112796T1 (el) | Μεθανοσουλφονικος 3-[(2{[4-(εξυλοξυκαρβοονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]μεθυλ}-1-μεθυλ-1h-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικος αιθυλεστερας | |
| EP1816988A4 (en) | SIGMOID-NOTCH IMPLANT | |
| AU2003227360A1 (en) | Novel amide derivatives or salts thereof | |
| ATE464297T1 (de) | Verbessertes verfahren zur herstellung vom rosuvastatin calcium salz | |
| ATE243426T1 (de) | Verbessertes verfahren zur bekämpfung von unkraut mit glyphosat-herbizid | |
| JP2009520682A5 (enExample) | ||
| JP2004149545A5 (enExample) | ||
| JP2007520206A5 (enExample) | ||
| JP2007119504A5 (enExample) | ||
| PL370850A1 (pl) | Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli |